To be an ally or an adversary in bladder cancer: The NF-κB story has not unfolded

Carcinogenesis

Volumn 36, Issue 3, 2014, Pages 299-306

  Mukherjee, Neelam ^a   Houston, Tiffani J ^a   Cardenas, Eduardo ^a   Ghosh, Rita ^a,b  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

BLADDER CANCER; HISTONE UBIQUITINATION; HUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN FAMILY; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; BLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NF-KAPPA B; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84924503690     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu321     Document Type: Review

References (73)

1. Sen, R. et al. (1986) Inducibility of kappa immunoglobulin enhancerbinding protein Nf-kappa B by a posttranslational mechanism. Cell, 47, 921-928.
2. Perkins, N. (2012) The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer, 12, 121-132.
3. Ghosh, G. et al. (1995) Structure of NF-kappa B p50 homodimer bound to a kappa B site. Nature, 373, 303-310.
4. Baldwin, A. (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol., 14, 649-683.
5. Oeckinghaus, A. et al. (2009) The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol., 1, a000034.
6. Baeuerle, P. et al. (1994) Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol., 12, 141-179.
7. Bonizzi, G. et al. (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol., 25, 280-288.
8. Karin, M. et al. (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov., 3, 17-26.
9. Kato, T. et al. (2003) CK2 Is a C-Terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol. Cell, 12, 829-839.
10. Huang, T.T. et al. (2003) Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell, 115, 565-576.
11. Hoesel, B. et al. (2013) The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer, 12, 86.
12. Godwin, P. et al. (2013) Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front. Oncol., 3, 120.
13. Hatada, E. et al. (1992) The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding. Proc. Natl. Acad, Sci. USA, 89, 2489-2493.
14. Huxford, T. et al. (1998) The crystal structure of the IkappaBalpha/NFkappaB complex reveals mechanisms of NF-kappaB inactivation. Cell, 95, 759-770.
15. Johnson, C. et al. (1999) An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IkappaBalpha. EMBO J., 18, 6682-6693.
16. Chen, Z. et al. (1996) Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell, 84, 853-862.
17. Mercurio, F. et al. (1997) IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science (New York, N.Y.), 278, 860-866.
18. Ozes, O. et al. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature, 401, 82-85.
19. Zandi, E. et al. (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell, 91, 243-252.
20. May, M. et al. (2002) Characterization of the Ikappa B-kinase NEMO binding domain. J. Biol. Chem., 277, 45992-46000.
21. May, M. et al. (2000) Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science (New York, N.Y.), 289, 1550-1554.
22. Ling, L. et al. (1998) NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. USA, 95, 3792-3797.
23. Scheidereit, C. (2006) IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene, 25, 6685-6705.
24. Hayden, M.S. et al. (2004) Signaling to NF-kappaB. Genes Dev., 18, 2195-224.
25. Xiao, G. et al. (2004) Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J. Biol. Chem., 279, 30099-30105.
26. Huang, B. et al. (2010) Posttranslational modifications of NF-kappaB:another layer of regulation for NF-kappaB signaling pathway. Cell. Signal., 22, 1282-1290.
27. Zhong, H. et al. (1997) The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMPindependent mechanism. Cell, 89, 413-424.
28. Jamaluddin, M. et al. (2007) TNF-alpha-induced NF-kappaB/RelA Ser(276) phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell. Signal., 19, 1419-1433.
29. Sakurai, H. et al. (1999) IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem., 274, 30353-30356.
30. Buss, H. et al. (2004) Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J. Biol. Chem., 279, 49571-49574.
31. Mattioli, I. et al. (2006) Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon. J. Biol. Chem., 281, 6175-6183.
32. Kiernan, R. et al. (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem., 278, 2758-2766.
33. Chen, L.-f. et al. (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J., 21, 6539-6548.
34. Yeung, F. et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 23, 2369-2380.
35. Lu, T. et al. (2010) Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc. Natl. Acad. Sci. USA, 107, 46-51.
36. Ganesh, L. et al. (2006) Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis. Mol. Cell. Biol., 26, 3864-3874.
37. Levy, D. et al. (2011) Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat. Immunol., 12, 29-36.
38. Natoli, G. et al. (2008) Nuclear ubiquitin ligases, NF-kappaB degradation, and the control of inflammation. Sci. Signal., 1, pe1.
39. Ryo, A. et al. (2003) Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/ RelA. Mol. Cell, 12, 1413-1426.
40. Rodrigues, L. et al. (2009) Termination of NF-kappaB activity through a gammaherpesvirus protein that assembles an EC5S ubiquitin-ligase. EMBO J., 28, 1283-1295.
41. Gilmore, T.D. (1999) Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene, 18, 6925-6937.
42. Rayet, B. et al. (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene, 18, 6938-6947.
43. Garg, A. et al. (2002) Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia, 16, 1053-1068.
44. Baldwin, A. (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest., 107, 241-246.
45. Karin, M. et al. (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2, 301-310.
46. Ryan, K.M. et al. (2000) Role of NF-kappaB in p53-mediated programmed cell death. Nature, 404, 892-897.
47. Seitz, C.S. et al. (1998) Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc. Natl. Acad. Sci. USA, 95, 2307-2312.
48. Jacque, E. et al. (2013) RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation. Oncogene, 32, 2661-2669.
49. Perkins, N. et al. (2006) Good cop, bad cop: the different faces of NFkappaB. Cell Death Differ., 13, 759-772.
50. Dahm, P. et al. (2003) Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur. Urol., 44, 672-681.
51. Kontos, S. et al. (2010) Inverse expression of estrogen receptor-beta and nuclear factor-kappaB in urinary bladder carcinogenesis. Int. J. Urol. 17, 801-809.
52. Kontos, S. et al. (2010) Coordinated increased expression of Cyclooxygenase2 and nuclear factor κB is a steady feature of urinary bladder carcinogenesis. Adv. Urol., 2010. doi: 10.1155/2010/871356.
53. Kang, S. et al. (2005) Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett., 217, 11-16.
54. Riemann, K. et al. (2007) Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int. J. Clin. Pharmacol.Ther., 45, 423-430.
55. Tang, T. et al. (2010) Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese. DNA Cell Biol., 29, 9-12.
56. Li, P. et al. (2013) Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PloS One, 8, e71604. doi: 10.1371/journal.pone.0071604.
57. Levidou, G. et al. (2008) Clinical significance of nuclear factor (NF)- kappaB levels in urothelial carcinoma of the urinary bladder. Virchows Archiv., 452, 295-304.
58. Kadhim, H. et al. (2006) Possible role of nuclear factor kappaB detected by in situ hybridization in the pathogenesis of transitional cell carcinoma of the bladder. J. Med. Liban., 54, 196-199.
59. Netto, G. (2013) Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a "mirage"? Adv. Anat. Pathol.,. 20, 175-203.
60. Cancer Genome Atlas Research Network. (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315-322.
61. Sanchez-Carbayo, M. et al. (2003) Gene discovery in bladder cancer progression using cDNA microarrays. Am. J. Pathol., 163, 505-516.
62. Mian, B. et al. (2003) Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via downregulation of matrix metalloproteases and nuclear factor-kappaB. Clin. Cancer Res., 9, 3167-3175.
63. Karashima, T. et al. (2003) Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin. Cancer Res., 9, 2786-2797.
64. Chen, R.-J. et al. (2008) Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol. Sci., 104, 283-293.
65. Zhu, Z. et al. (2012) Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm., 2012, 528690.
66. Dyrskjøt, L. et al. (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res., 69, 4851-4860.
67. Modlich, O. et al. (2004) Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin. Cancer Res., 10, 3410-3421.
68. Blaveri, E. et al. (2005) Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res., 11, 4044-4055.
69. Lee, J.-S. et al. (2010) Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol., 28, 2660-2667.
70. Thapa, D. et al. (2014) NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis. Cancer Res., 74, 5644-5655.
71. Holmäng, S. et al. (1995) The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol., 153, 1823.
72. Kamat, A.M. et al. (2009) Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res., 69, 8958-8966.
73. Ahirwar, D. et al. (2010) IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort. Arch. Med. Res., 41, 97-103.